Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9.
Cullot G, Boutin J, Fayet S, Prat F, Rosier J, Cappellen D, Lamrissi I, Pennamen P, Bouron J, Amintas S, Thibault C, Moranvillier I, Laharanne E, Merlio JP, Guyonnet-Duperat V, Blouin JM, Richard E, Dabernat S, Moreau-Gaudry F, Bedel A. Cullot G, et al. Among authors: guyonnet duperat v. Nat Commun. 2023 Jul 10;14(1):4072. doi: 10.1038/s41467-023-39632-w. Nat Commun. 2023. PMID: 37429857 Free PMC article.
FGFR3 has tumor suppressor properties in cells with epithelial phenotype.
Lafitte M, Moranvillier I, Garcia S, Peuchant E, Iovanna J, Rousseau B, Dubus P, Guyonnet-Dupérat V, Belleannée G, Ramos J, Bedel A, de Verneuil H, Moreau-Gaudry F, Dabernat S. Lafitte M, et al. Mol Cancer. 2013 Jul 31;12:83. doi: 10.1186/1476-4598-12-83. Mol Cancer. 2013. PMID: 23902722 Free PMC article.
Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes.
Mélard P, Idrissi Y, Andrique L, Poglio S, Prochazkova-Carlotti M, Berhouet S, Boucher C, Laharanne E, Chevret E, Pham-Ledard A, De Souza Góes AC, Guyonnet-Duperat V, Bibeyran A, Moreau-Gaudry F, Vergier B, Beylot-Barry M, Merlio JP, Cappellen D. Mélard P, et al. Oncotarget. 2016 Oct 18;7(42):68734-68748. doi: 10.18632/oncotarget.11930. Oncotarget. 2016. PMID: 27626696 Free PMC article.
CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations.
Cullot G, Boutin J, Toutain J, Prat F, Pennamen P, Rooryck C, Teichmann M, Rousseau E, Lamrissi-Garcia I, Guyonnet-Duperat V, Bibeyran A, Lalanne M, Prouzet-Mauléon V, Turcq B, Ged C, Blouin JM, Richard E, Dabernat S, Moreau-Gaudry F, Bedel A. Cullot G, et al. Nat Commun. 2019 Mar 8;10(1):1136. doi: 10.1038/s41467-019-09006-2. Nat Commun. 2019. PMID: 30850590 Free PMC article.
CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells.
Boutin J, Rosier J, Cappellen D, Prat F, Toutain J, Pennamen P, Bouron J, Rooryck C, Merlio JP, Lamrissi-Garcia I, Cullot G, Amintas S, Guyonnet-Duperat V, Ged C, Blouin JM, Richard E, Dabernat S, Moreau-Gaudry F, Bedel A. Boutin J, et al. Among authors: guyonnet duperat v. Nat Commun. 2021 Aug 13;12(1):4922. doi: 10.1038/s41467-021-25190-6. Nat Commun. 2021. PMID: 34389729 Free PMC article.
CRISPR editing to mimic porphyria combined with light: A new preclinical approach for prostate cancer.
Boutin J, Genevois C, Couillaud F, Lamrissi-Garcia I, Guyonnet-Duperat V, Bibeyran A, Lalanne M, Amintas S, Moranvillier I, Richard E, Blouin JM, Dabernat S, Moreau-Gaudry F, Bedel A. Boutin J, et al. Among authors: guyonnet duperat v. Mol Ther Oncol. 2024 Feb 8;32(1):200772. doi: 10.1016/j.omton.2024.200772. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596305 Free PMC article.
36 results